Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

doi:10.1002/ejp.1301

Paper

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

Published Sep 17, 2018 · Timothy Fung, Y. Asiri, K. Taheri

European Journal of Pain

1

Citations

0

Influential Citations

Full text

Abstract

Neuraxial opioids are widely used for intraoperative and post‐operative analgesia. The risk of severe adverse effects including respiratory depression accompanies this analgesia, prompting the need for effective non‐opioid alternatives. Systemic 1‐amino‐1‐cyclobutanecarboxylic acid showed promise in preliminary studies to produce antinociception without observable toxicity. However, the effects of 1‐amino‐1‐cyclobutanecarboxylic acid after intrathecal administration are unknown. The aim of this study was to determine whether intrathecal administration of 1‐amino‐1‐cyclobutanecarboxylic acid produces antinociceptive effects in murine models and to elucidate its site and receptor mechanism of action.

Non-RCTAnimal Study

Study Snapshot

Intrathecal administration of 1amino-1cyclobutanecarboxylic acid (ACB) effectively reduces pain in mice, offering a potential non-opioid alternative for intraoperative and post-operative analgesia.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

References

Citations